Influenza and other respiratory virus infections in solid organ transplant recipients  by Manuel, O. et al.
Inﬂuenza and other respiratory virus infections in solid organ transplant
recipients
O. Manuel1, F. Lopez-Medrano2, L. Kaiser3, T. Welte4, J. Carratala5,6, E. Cordero7, H. H. Hirsch8 on behalf of the ESCMID Study
Group of Infection in Compromised Hosts (ESGICH)
1) Infectious Diseases Service and Transplantation Center, University Hospital and University of Lausanne, Lausanne, Switzerland, 2) Unit of Infectious Diseases,
Hospital Universitario ‘12 de Octubre’, Instituto de Investigacion Hospital ‘12 de Octubre’ (i+12), School of Medicine, Universidad Complutense, Madrid, Spain, 3)
Division of Infectious Diseases and Division of Laboratory Medicine, University of Geneva Hospitals, Geneva, Switzerland, 4) Department of Respiratory Medicine,
Hannover Medical School, Hannover, Germany, 5) Department of Infectious Disease, Hospital Universitari de Bellvitge, 6) Insitut d’Investigacio Biomedica de
Bellvitge (IDIBELL), L’Hospitalet de Llobregat, University of Barcelona, Barcelona, 7) Hospital Universitario Virgen del Rocıo, Instituto de Biomedicina de Sevilla,
Seville, Spain and 8) Transplantation and Clinical Virology, Department of Biomedicine (Haus Petersplatz), University of Basel, Basel, Switzerland
Abstract
Community-acquired respiratory viruses (CARVs) are a frequent cause of disease in solid organ transplant (SOT) recipients. Lower
respiratory tract infections with CARVs can be associated with signiﬁcant morbidity and even mortality in this population. This article
reviews the clinical manifestations of CARVs infections and summarizes the evidence-based recommendations on the preventive and
therapeutic strategies to decrease the burden of these viral infections in SOT recipients.
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Hot topics
 Community-acquired respiratory viruses (CARVs) are a
frequent cause of disease in solid organ transplant (SOT)
recipients. Lower respiratory tract infections with CARV
can be associated with signiﬁcant morbidity and even
mortality in this population
 The impact of CARV infections on the progression of
chronic allograft dysfunction in lung transplant recipients
remains controversial
 Among CARVs, inﬂuenza infection may particularly present
with severe disease in SOT recipients. The main risk factors
for severe inﬂuenza infection are a shorter time from
transplant and the presence of pneumonia
 Nucleic acid ampliﬁcation testing (NAT) has become the
main diagnostic method for detecting CARVs in clinical
specimens. NAT is signiﬁcantly more sensitive than other
methods such as direct antigen detection or virus isolation
by cell culture
 Infection control measures remain an essential element in
decreasing the burden of CARVs in SOT recipients
 The main strategy for preventing inﬂuenza is yearly admin-
istration of the inactivated inﬂuenza vaccine, and it is highly
recommended after transplantation. While most studies
have shown a reduction in the immunogenicity of inﬂuenza
vaccine in SOT recipients, some degree of efﬁcacy is
expected in this population
 The role of palivizumab or IVIG in preventing respiratory
syncytial virus (RSV) infection in SOT recipients has not
been established
 The use of antiviral therapy with neuraminidase inhibitors is
associated with improved outcomes in SOT recipients,
irrespective of the duration of symptoms. Antiviral therapy
should be empirically administered to all SOT recipients
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with inﬂuenza-like symptoms during the inﬂuenza season
while waiting for microbiological conﬁrmation
 The efﬁcacy of ribavirin (aerosolized or oral) for the
treatment of RSV infection in SOT recipients has not been
determined
Introduction
Community-acquired respiratory virus (CARV) infections are a
common cause of medical consultations and hospitalizations in
solid organ transplant (SOT) recipients [1]. They are caused by
a variety of RNA viruses, including inﬂuenza A and B,
respiratory syncytial virus (RSV), parainﬂuenza virus (PIV),
rhinovirus (hRV), human metapneumovirus (hMPV) and cor-
onavirus. In addition, DNA viruses, such as adenovirus,
polyomavirus, and bocavirus, may also be responsible for
cases of respiratory tract infection. While the majority of
infections due to CARV are restricted to the upper respira-
tory tract (URT), SOT recipients, due to alterations in cellular
and humoral immunity, are at a higher risk of developing
progression to the lower respiratory tract (LRT) [2]. CARV
LRT infections are associated with signiﬁcant morbidity in SOT
recipients. Speciﬁcally in lung transplant recipients, CARV LRT
infections may be associated with a higher incidence of chronic
lung allograft dysfunction (CLAD), although the literature on
this topic is controversial [3]. While all viruses share similar
clinical manifestations, inﬂuenza viruses appear to be particu-
larly associated with impaired outcomes in SOT recipients [4].
The 2009 inﬂuenza A pandemic has led to epidemiological
studies assessing the clinical manifestations and outcomes of
inﬂuenza A infection [5,6], as well as clinical trials on the
efﬁcacy of preventive strategies for inﬂuenza, including in SOT
recipients [7,8]. Also the routine use of molecular methods for
detecting other CARVs has increased our knowledge on their
epidemiology and their direct and indirect effects on SOT
outcomes [9].
Given the updated knowledge on the topic, a panel of
European experts in the management of viral infections in
transplant patients has developed evidence-based recommen-
dations for the management of CARVs in SOT recipients.
Epidemiology and Clinical Manifestations of
CARV Infections in SOT Recipients
Inﬂuenza viruses
Inﬂuenza is an acute, usually self-limiting, febrile illness that
occurs every winter season. Infection with inﬂuenza virus can
occur at any time after transplantation, and it appears to be
most severe in the early post-transplant period (<3 months)
[10]. The risk of inﬂuenza is also related to the type of organ
transplant. In a study involving 3569 SOT recipients, the
incidence of inﬂuenza was 41.8, 4.3 and 2.8 cases/1000
person-years among lung, kidney and liver transplant recipients,
respectively [4]. Similarly, studies performed during the pan-
demic documented that the incidence of inﬂuenza A/H1N1
infection was higher in recipients of lungs (30–400 cases per
1000 person-years) than in recipients of other organs, such as
the kidney (19–22 cases per 1000 person-years), liver (29 cases
per 1000 person-years) or heart (37 cases per 1000 patient--
years) [11,12]. Fewer data are available regarding the epidemi-
ology of inﬂuenza B virus infection in transplant recipients.
Some series have reported that inﬂuenza B virus may cause up
to one-fourth of the total number of inﬂuenza cases [13,14], but
it is not known whether inﬂuenza B virus infection may be
associated with different outcomes in SOT recipients.
The clinical features of inﬂuenza in SOT recipients do not
considerably differ from those described in the general
population. Inﬂuenza should be clinically suspected in all SOT
recipients presenting with respiratory symptoms such as fever,
rhinorrhea, cough and sore throat, with or without myalgias
and headaches and dyspnoea during the inﬂuenza season
[4,15]. However, fever may be missing, and the usually abrupt
onset may be delayed in immunocompromised patients [16].
Therefore, a proposal has been made to modify the deﬁnitions
of inﬂuenza-like illness provided by the ECDC to better
capture the presentation in immunocompromised patients
[17]. Basically, the deﬁnition of CARV disease includes: (i) a
new onset of symptoms and (ii) at least one of the following
four respiratory symptoms (cough, sore throat, shortness of
breath and coryza) and (iii) the clinician’s judgment that the
illness is due to an infection. The occurrence of pneumonia in
SOT recipients with inﬂuenza infection ranges from 14% to
49%, and bilateral involvement is frequently observed [4–6].
Bacterial, viral or fungal co-infection is relatively common in
SOT recipients and reported co-infection frequency ranges
from 7% to 29% [5,18]. An increased risk of acute and chronic
allograft rejection also has been associated with infection by
inﬂuenza and other respiratory viruses [4,5,11]. In lung
transplant recipients, inﬂuenza has been linked to the occur-
rence of chronic lung allograft dysfunction (CLAD) [12,19],
although not consistently in all studies [3]. Other less frequent
complications of inﬂuenza in SOT recipients include enceph-
alitis, myocarditis and myositis. Inﬂuenza in SOT recipients has
been associated with high rates of medical complications and
even mortality [4–6]. The main risk factors associated with
impaired outcomes are the presence of pneumonia and
diabetes mellitus, the use of antilymphocyte globulin
(<6 months), and delayed antiviral therapy [10].
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Respiratory Syncytial Virus
RSV is one of the more common causes of respiratory tract
infection during childhood. The epidemiology and clinical
characteristics of RSV infection are incompletely determined in
SOT recipients; most studies have included only lung trans-
plant recipients [9,20]. The incidence of RSV infection may
range from 2.4% to 15% of all CARV infections occurring in
SOT recipients [9,20–22]. Clinical manifestations of RSV
infection in SOT recipients include fever, cough and dyspnoea.
Ground-glass opacities and lung nodules are common ﬁndings
on CT scans in cases of LRT disease [23]. Recent data suggest
that RSV infection is currently a rare cause of hospitalization
and mortality among SOT recipients [9,20]. In lung transplant
recipients, RSV LRT disease appears to contribute to the
development of CLAD, but it is not associated with acute
rejection [3].
Parainﬂuenza Virus
Parainﬂuenza is a paramyxovirus for which four species (PIV-1,
-2, -3 and -4) are described. PIV-1 and PIV-2 show a
pronounced seasonality in the autumn, whereas PIV-3 is more
frequently detected in spring. Incidence of PIV infection in SOT
recipients varies between 3.4% and 20% of all CARV infections
[9,21,22]. While clinical manifestations of PIV infection in SOT
recipients are not different to those seen in other CARV
infections, some severe cases of PIV disease have been
described, especially in children [24]. A recent study showed
a higher incidence of hospitalization in lung transplant recip-
ients with PIV infection (50%) as compared with infection with
other CARVs (16.9%) [9].
Rhinovirus
Human rhinovirus is a picornavirus that is the most frequent
cause of the common cold in the general population. In SOT
recipients, rhinovirus is the respiratory virus most commonly
identiﬁed in prospective studies assessing the incidence of
CARV infections [9]. Infections with rhinovirus are usually mild
and self-limiting, although some cases of severe LRT disease
and chronic viral shedding have been described in lung
transplant recipients [25]. Rhinovirus appears to be less
commonly associated with CLAD than other respiratory
viruses.
Other CARVs
Clinical characteristics of adenovirus, hMPV and coronavirus
infections are similar to those seen with other CARVs. The
clinical signiﬁcance of newly discovered viruses such as
polyomaviruses (WU and KI virus) or bocavirus in the
transplant population has not completely been determined
[26].
Diagnostics of CARV Infections
In 2014, nucleic acid ampliﬁcation testing (NAT) has become
the main diagnostic method for detecting CARVs in clinical
specimens. NAT has proved to be signiﬁcantly more sensitive
than other methods such as direct antigen detection or virus
isolation by cell culture. This increased sensitivity is also
associated with an excellent speciﬁcity, particularly when the
detection of the ampliﬁed product uses a speciﬁc probe [27].
At this time NAT are frequently based on the real-time PCR
technology and present theoretically the following advantages:
they could detect viral load as low as few copies of genome
equivalent introduced into the ampliﬁcation reaction, the
analytical speciﬁcity approaches 100%, and the technique can
provide semi-quantitative results. A challenge for CARV
detection is related to the number of different agents that
need to be detected, which may encompass 16 or more
different viral species, types or subtypes depending on the
completeness of the screening and the spectrum of agents
targeted [27]. The technical solution adopted (e.g. multiplex-
ing) could impact the performance and possibly decrease the
sensitivity.
Rapid inﬂuenza diagnostic tests have appropriate speciﬁcity,
but low sensitivity, so that their performance in the diagnosis
of inﬂuenza (and particularly in clinical decision-making for
antiviral therapy) in the immunocompromised host appears to
be suboptimal.
Nasopharyngeal specimens collected with a swab are the
most convenient and effective respiratory specimens for the
initial screening of viral respiratory viruses; pooled nasopha-
ryngeal and pharyngeal specimens are used by some and could
possibly increase the sensitivity along with decreasing variabil-
ity of results. In cases of LRT disease, bronchoalveolar lavage
(BAL) is the preferred specimen for diagnostic testing of
CARVs. This is particularly important, as patients with LRT
disease may present with a negative test for the nasopharyn-
geal swab.
Respiratory specimens are not standardized: this limits the
ability to provide reproducible quantitative assays although the
real-time technology offers the opportunity to semi-quantita-
tively assess the viral load. Therefore, one should be cautious
not to over-interpret quantitative results. Also, the duration of
viral shedding using sensitive molecular assays can be signiﬁ-
cantly longer compared with immunocompetent adults. In
immunocompetent adults we expect a rapid viral clearance and
nucleic acid detection to be negative within 7–10 days.
Prolonged shedding for weeks and months is a common
occurrence in highly immunocompromised individuals [16,28].
Particularly for inﬂuenza, protocols for establishing the best
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 7), 102–108
104 Clinical Microbiology and Infection, Volume 20 Supplement 7, September 2014 CMI
frequency for viral testing and appropriate cut-offs for
discontinuation of antiviral therapy in SOT recipients have
not been described.
Prevention of CARV Infections (Table 1)
Infection control measures remain an essential element for
decreasing the burden of CARVs in SOT recipients. Overall
awareness among healthcare personnel and caregivers about
the potential deleterious outcomes of CARV infections in SOT
recipients and the importance of early detection of infection
may have a major impact on the incidence of CARV infections
and subsequent complications. More speciﬁcally, hand hygiene
and adherence to contact and respiratory droplet isolation will
help reduce CARV infections in SOT recipients. These
infection control measures need to be taken until the patient
is sent home or until PCR is negative.
The inﬂuenza virus is currently the only CARV that can be
prevented with vaccination [29]. The few studies assessing the
clinical effectiveness of inﬂuenza vaccine in SOT recipients have
reported an overall low rate of clinical failures of vaccination
(ranging from 1.1% to 3.6% with the use of adjuvanted vaccines
during the pandemic), although this is also dependent on the
matching between the vaccine and the circulating strains [30,31].
In addition, patients who developed symptomatic inﬂuenza
infection after vaccination had a 70% reduced risk of subsequent
pneumonia [32]. In a large registry of kidney transplant
recipients, inﬂuenza vaccination during the ﬁrst year after
transplantation was associated with a reduced incidence of graft
loss andmortality [33]. However, data on the immunogenicity of
inﬂuenza vaccination in the transplant population are contro-
versial and most published studies suggest that a reduced
humoral immune response is expected in SOT recipients
[29,34]. Lung transplant recipients appear to have a poorer
response than recipients of other allografts, probably related to
the higher degree of immunosuppression needed after lung
transplantation and the allogeneic constellation between
virus-infected host cells and effector T cells [8]. The use of
mycophenolatemofetil andmTOR inhibitors has been related to
a weaker response to inﬂuenza vaccine in some studies
[8,35,36], but not in others [37]. Responses to inﬂuenza B virus
are usually weaker than those seenwith inﬂuenza A viruses [38].
Different strategies have been proposed to improve the
immunogenicity of inﬂuenza vaccine in SOT recipients, includ-
ing administration of a boosting dose, intradermal vaccination,
higher doses of vaccine antigen and the use of adjuvanted
vaccines. Adjuvanted vaccines with MF59 or AS03 adjuvants
have proven improved efﬁcacy in the elderly [39], and an overall
increased immunogenicity in transplant recipients [7,8]. How-
ever, there are not enough data in the transplant population to
currently recommend speciﬁcally any of these approaches [29].
Household members and healthcare workers in contact with
SOT recipients should also receive inﬂuenza vaccination.
Additional pneumococcal vaccination (and particularly the
administration of the 13-valent pneumococcal conjugate vac-
cine) should be proposed for SOT recipients to potentially
reduce the risk for inﬂuenza-related complications [40].
Inactivated inﬂuenza vaccine is generally well tolerated in
SOT recipients. Some reports during the pandemic found an
increased rate of de novo anti-HLA antibodies after the
administration of adjuvanted inﬂuenza vaccine, although with-
out clinical signiﬁcance at 1 year [41]. Subsequent studies have
not conﬁrmed these results [38]. Inﬂuenza vaccine is usually
recommended 3–6 months after transplantation, in order to
avoid any temporal relationship between vaccination and acute
rejection during the period when the patient is at higher risk of
allograft rejection [29]. Some studies have shown an appro-
priate antibody response and safety proﬁle also if the vaccine is
administered during the ﬁrst weeks post-transplant [35].
Overall, the need for protection against inﬂuenza in SOT
recipients clearly outweighs the theoretical safety concerns of
vaccination.
No vaccine is yet available for RSV. There is very limited
experience with the use of immunoprophylaxis with non-spe-
ciﬁc intravenous immunoglobulin (IVIG), RSV-IVIG or pali-
vizumab (a monoclonal antibody speciﬁc for the RSV-F
protein) for prevention of RSV infection in SOT recipients.
Palivizumab may be considered for children <2 years old
during the RSV season [42]. However, the high cost of
palivizumab combined with a lack of clear evidence of efﬁcacy
in SOT recipients precludes their wide-scale use.
Treatment of CARV Infections (Table 2)
Upper respiratory tract disease caused by CARVs can be
symptomatically treated with analgesics, anti-inﬂammatory
drugs and nasal decongestants. Due to the risk of developing
Reye0s syndrome, salicylates should be avoided in children and
adolescents with inﬂuenza-like symptoms. In cases of LRT
disease (including pneumonia), bacterial or fungal infection
must be ruled out or appropriately treated. Empirical antibiotic
therapy should be directed against Streptococcus pneumoniae,
Haemophilus inﬂuenzae and Staphylococcus aureus.
Speciﬁc antiviral treatment for infection by inﬂuenza virus
Adequate antiviral therapy should be initiated, as soon as
possible, in all SOT recipients with suspected inﬂuenza
infection [4,10]. This recommendation is made irrespective
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of the duration of the symptoms and the severity of illness. In
any case, antiviral treatment of inﬂuenza-like illness should not
be delayed by waiting for microbiological conﬁrmation, but
rather discontinued when appropriate test results are negative.
Early speciﬁc antiviral treatment should be especially encour-
aged in cases of pneumonia. Two classes of antiviral drugs are
currently approved for treatment of inﬂuenza infection: M2
inhibitors (amantadine and rimantadine), which are active only
against inﬂuenza A, and neuraminidase inhibitors (oseltamivir
and zanamivir). Other drugs under investigation are parenteral
zanamivir and peramivir. M2 inhibitors are not currently
recommended due to resistance of most circulating inﬂuenza
A strains and the variable, but at times predominant, circula-
tion of inﬂuenza B. Neuraminidase inhibitors are usually well
tolerated, with the most common adverse effects being
gastrointestinal symptoms. In children, the use of oseltamivir
has been associated with neuropsychiatric adverse events.
Inhaled zanamivir (two puffs, 10 mg, twice daily) does not
require dose adjustment either for hepatic or renal failure.
Oral oseltamivir (75 mg twice daily) dose adjustment is not
needed in hepatic impairment but doses should be modiﬁed in
renal insufﬁciency according to the recommendations included
in Table 3. Proven beneﬁts of higher doses of oseltamivir in
SOT recipients with severe inﬂuenza infection are lacking [43].
If available, intravenous zanamivir or peramivir can be consid-
ered in SOT recipients who are severely ill despite oral
oseltamivir, in patients in whom oral absorption is a concern,
or in those with suspected or conﬁrmed oseltamivir resis-
tance. Duration of antiviral therapy is 5 days in mild cases of
inﬂuenza, but it can be prolonged in more severe cases with
protracted evolution until viral load in the nasopharyngeal
swab is undetectable. Pregnancy is not a contraindication for
the administration of oseltamivir and pregnant women should
be encouraged to receive inﬂuenza vaccination.
Development of oseltamivir resistance is promoted by the
lack of an efﬁcient immune response, high viral load and
prolonged viral shedding, frequently observed in immunocom-
promised hosts [44]. Resistance should be suspected when
prolonged shedding over c. 10 days is observed. Resistance is
diagnosed by specialized laboratories using genotypic or
phenotypic assays. When resistance to oseltamivir develops,
strains are generally cross-resistant to peramivir but most of
them remain susceptible to zanamivir, and hence parenteral
zanamivir (compassionate use) is an option. Transmission of
resistant strains has been occasionally described in high-risk
hospital wards [45]. Cross-resistance to all available neur-
aminidase inhibitors has been described and underscores the
need for new therapies.
Speciﬁc treatment for infection by other respiratory virus
infections
The use of ribavirin for the treatment of RSV infection is
controversial. Nevertheless, some experts consider ribavirin
for the treatment of severe forms of LRT disease in SOT
recipients [17]. Aerosolized ribavirin can be administered as
2 g for 2 h every 8 h or as 6 g over 18 h/day for 7–10 days.
Appropriate precautions should be taken to avoid environ-
TABLE 1. Recommendations on prevention of commu-
nity-acquired respiratory virus infection
SOT recipients should avoid close contact with individuals with respiratory tract
infections. AII
All SOT recipients and candidates should receive annual seasonal inﬂuenza
vaccination. AII
Household members and HCWs in contact with SOT recipients should also
receive inﬂuenza vaccination. AII
Live-attenuated inﬂuenza vaccine is not recommended in SOT recipients. DII
In selected patients to whom inﬂuenza vaccine cannot be administered,
prophylaxis with oseltamivir 75 mg/day for 12 weeks during the inﬂuenza season
may be proposed. CI
The use of palivizumab for prevention of respiratory syncytial virus infection is not
recommended in SOT recipients. CIII
SOT, solid organ transplant; HCW, healthcare workers.
TABLE 2. Recommendations for treatment of commu-
nity-acquired respiratory virus infection
Antiviral therapy with oseltamivir or zanamivir should be administered to solid
organ transplant (SOT) recipients with a clinical suspicion of inﬂuenza infection,
before laboratory conﬁrmation, irrespective of the duration of symptoms. AII
Treatment of inﬂuenza with M2 inhibitors (amantadine and rimantadine) is not
recommended. DII
In the absence of a concern over drug absorption, a double dose of oseltamivir
(i.e. 150 mg BID) is not recommended. CI
The use of intravenous zanamivir or peramivir can be considered in patients not
responding to oseltamivir therapy or for whom oral absorption is a concern. BII
In severe cases of low respiratory tract infection with respiratory syncytial virus
(RSV) and parainﬂuenza virus (PIV) infections in SOT recipients, therapy with
aerosolized or oral ribavirin may be used. BII
Intravenous immunoglobulin can be combined with antiviral therapy in severe
cases of RSV and PIV infection. BIII
There are insufﬁcient data to recommend therapy with ribavirin in lung transplant
recipients with non-severe cases of RSV or PIV infection. CIII
The use of ribavirin may be considered in severe cases of hMPV infection. CIII
TABLE 3. Oseltamivir doses for adult patients with normal
renal function or renal function impairment and for those
under renal replacement therapies and other extracorporeal
therapies
Doses for treatment
75 mg ﬁrst dose in
all cases, then:
GFR >60 mL/min 75 mg BID
GFR 30–60 mL/min 75 mg BID
GFR <30 mL/min 75 mg OD
Haemodialysis 30–75 mg after
haemodialysis sessiona
Peritoneal dialysis 30 mg ODa
Continuous renal
replacement therapy
75 mg OD
Extracorporeal
membrane oxygenation
Standard treatment according
to renal function
GFR, glomerular ﬁltration rate; BID, twice daily; OD, once daily; SD, single dose.
aDose administered after the session.
Adapted from [59].
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mental teratogenic exposure in pregnant healthcare workers
and visitors when aerosolized ribavirin is used. A few reports
have reported the use of systemic ribavirin for RSV disease:
orally or intravenously as 10–30 mg/kg of body weight in
three divided doses [46–50]. Patients treated with systemic
ribavirin should be checked for haemolysis, abnormal liver
function and kidney failure. Of note, there are few data about
the potential impact of the use of ribavirin on the prevention
of indirect effects in lung transplant recipients with RSV
infection [51].
For the treatment of severe forms of PIV infection, there is
marginal experience with the use of ribavirin with or without
intravenous immunoglobulin and steroids [52–54]. Ribavirin
was used for the treatment of LRT disease caused by
coronavirus during the outbreak of severe acute respiratory
syndrome (SARS); however, there are no data to recommend
ribavirin for the treatment of coronavirus infection in SOT
recipients [55]. For the management of severe hMPV infection,
supportive care is the main treatment, although anecdotal
reports have been published about successful treatment with
ribavirin and intravenous immunoglobulin [56–58]. No speciﬁc
treatment is approved for rhinovirus infection.
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